These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32750572)

  • 41. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The McLean-Harvard First-Episode Project: Early Course in 114 Cases of First-Episode Nonaffective Psychoses.
    Tohen M; Khalsa HM; Salvatore P; Zarate CA; Strakowski SM; Sanchez-Toledo JP; Baldessarini RJ
    J Clin Psychiatry; 2016 Jun; 77(6):781-8. PubMed ID: 27232651
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome of schizoaffective disorder at two long-term follow-ups: comparisons with outcome of schizophrenia and affective disorders.
    Grossman LS; Harrow M; Goldberg JF; Fichtner CG
    Am J Psychiatry; 1991 Oct; 148(10):1359-65. PubMed ID: 1897617
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One-year outcome of low-intensity booster sessions versus care as usual in psychosis patients after a short-term psychoeducational intervention.
    Sibitz I; Amering M; Gössler R; Unger A; Katschnig H
    Eur Psychiatry; 2007 May; 22(4):203-10. PubMed ID: 17182222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Text Messaging Adherence Intervention for Adolescents and Young Adults with Chronic Kidney Disease: Pilot Randomized Controlled Trial and Stakeholder Interviews.
    Eaton C; Comer M; Pruette C; Psoter K; Riekert K
    J Med Internet Res; 2020 Aug; 22(8):e19861. PubMed ID: 32795983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Twenty year multi-follow-up of different types of hallucinations in schizophrenia, schizoaffective disorder, bipolar disorder, and depression.
    Goghari VM; Harrow M
    Schizophr Res; 2016 Oct; 176(2-3):371-377. PubMed ID: 27349816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mobile Text Messaging to Improve Medication Adherence and Viral Load in a Vulnerable Canadian Population Living With Human Immunodeficiency Virus: A Repeated Measures Study.
    King E; Kinvig K; Steif J; Qiu AQ; Maan EJ; Albert AY; Pick N; Alimenti A; Kestler MH; Money DM; Lester RT; Murray MCM
    J Med Internet Res; 2017 Jun; 19(6):e190. PubMed ID: 28572079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome studies of schizoaffective disorders.
    Samson JA; Simpson JC; Tsuang MT
    Schizophr Bull; 1988; 14(4):543-54. PubMed ID: 3064281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Maintenance electroconvulsive therapy and treatment of refractory schizophrenia].
    Lévy-Rueff M; Jurgens A; Lôo H; Olié JP; Amado I
    Encephale; 2008 Oct; 34(5):526-33. PubMed ID: 19068343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Randomized Trial of User-Controlled Text Messaging to Improve Asthma Outcomes: A Pilot Study.
    Britto MT; Rohan JM; Dodds CM; Byczkowski TL
    Clin Pediatr (Phila); 2017 Dec; 56(14):1336-1344. PubMed ID: 28056541
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Premorbid adjustment in schizophrenia and schizoaffective disorder.
    Saracco-Alvarez R; Rodríguez-Verdugo S; García-Anaya M; Fresán A
    Psychiatry Res; 2009 Feb; 165(3):234-40. PubMed ID: 19162333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
    Byerly MJ; Nakonezny PA; Rush AJ
    Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-yield cognitive behavioral techniques for psychosis delivered by case managers to their clients with persistent psychotic symptoms: an exploratory trial.
    Turkington D; Munetz M; Pelton J; Montesano V; Sivec H; Nausheen B; Kingdon D
    J Nerv Ment Dis; 2014 Jan; 202(1):30-4. PubMed ID: 24375209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
    Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
    J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Therapeutic benefit of a registered psychoeducation program on treatment adherence, objective and subjective quality of life: French pilot study for schizophrenia].
    Sauvanaud F; Kebir O; Vlasie M; Doste V; Amado I; Krebs MO
    Encephale; 2017 May; 43(3):235-240. PubMed ID: 27658989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An exploratory, randomized controlled trial of adherence therapy for people with schizophrenia.
    Anderson KH; Ford S; Robson D; Cassis J; Rodrigues C; Gray R
    Int J Ment Health Nurs; 2010 Oct; 19(5):340-9. PubMed ID: 20887608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson D; Woerner MG; Alvir JM; Bilder R; Goldman R; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Lieberman JA
    Arch Gen Psychiatry; 1999 Mar; 56(3):241-7. PubMed ID: 10078501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.